These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 23036785)

  • 21. Clinical characteristics of type 2 diabetic patients on basal insulin therapy with adequate fasting glucose control who do not achieve HbA1c targets.
    Mata-Cases M; Mauricio D; Franch-Nadal J
    J Diabetes; 2017 Jan; 9(1):34-44. PubMed ID: 26749415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Randomized Trial of Insulin Glargine plus Oral Hypoglycemic Agents versus Continuous Subcutaneous Insulin Infusion to Treat Newly Diagnosed Type 2 Diabetes.
    Lin S; Chen M; Chen W; Lin K; Mu P; Zhu B; Xu W; Wang M; Weng J; Zeng L
    J Diabetes Res; 2018; 2018():2791584. PubMed ID: 30420969
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of generic exenatide injection in Chinese patients with type 2 diabetes: a multicenter, randomized, controlled, non-inferiority trial.
    Yang J; Xiao W; Guo L; Li Q; Zhong L; Yang J; Yang J; Gao Y; Tian Q; Hong T
    Acta Diabetol; 2020 Aug; 57(8):991-1000. PubMed ID: 32206903
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Short-term intensive insulin therapy could be the preferred option for new onset Type 2 diabetes mellitus patients with HbA1c > 9.
    Weng J
    J Diabetes; 2017 Oct; 9(10):890-893. PubMed ID: 28661564
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of Recommendations for Diabetes Management at Hospital Discharge on Long-Term Diabetes Control.
    Shacham EC; Nitzan R; Schwartz N; Ishay A
    Endocr Pract; 2021 Feb; 27(2):118-123. PubMed ID: 33616045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-patient diabetes care: the impact of diabetes outreach team on long-term glycaemic control.
    Siddique H; Alam MM; Safi AW; Leong WB; Crowley K; Tahrani AA
    Int J Clin Pract; 2014 Nov; 68(11):1333-7. PubMed ID: 24837872
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial.
    Wang W; Nevárez L; Filippova E; Song KH; Tao B; Gu L; Wang F; Li P; Yang J
    Diabetes Obes Metab; 2019 Feb; 21(2):234-243. PubMed ID: 30129089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy.
    Lapolla A; Frison V; Bettio M; Dal Pos M; Rocchini P; Panebianco G; Tadiotto F; Da Tos V; D'Ambrosio M; Marangoni A; Ferrari M; Pianta A; Balzano S; Confortin L; Lamonica M; Marin N; Strazzabosco M; Brun E; Mesturino CA; Simoncini M; Zen F; Bax G; Bonsembiante B; Cardone C; Dal Frà MG; Gallo A; Masin M; Piarulli F; Sartore G; Simioni N
    Clin Ther; 2015 Mar; 37(3):574-84. PubMed ID: 25626486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distinct trajectories of HbA
    Rathmann W; Schwandt A; Hermann JM; Kuss O; Roden M; Laubner K; Best F; Ebner S; Plaumann M; Holl RW;
    Diabet Med; 2019 Nov; 36(11):1468-1477. PubMed ID: 31392761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of follow-up by a hospital diabetes care team on diabetes control at one year after discharge from the hospital.
    Garg R; Hurwitz S; Rein R; Schuman B; Underwood P; Bhandari S
    Diabetes Res Clin Pract; 2017 Nov; 133():78-84. PubMed ID: 28898714
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.
    Robinson AC; Burke J; Robinson S; Johnston DG; Elkeles RS
    Diabetes Care; 1998 May; 21(5):701-5. PubMed ID: 9589227
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM).
    Abraira C; Henderson WG; Colwell JA; Nuttall FQ; Comstock JP; Emanuele NV; Levin SR; Sawin CT; Silbert CK
    Diabetes Care; 1998 Apr; 21(4):574-9. PubMed ID: 9571345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glycemic control with insulin glargine as part of an ethnically diverse, community-based diabetes management program.
    Philis-Tsimikas A; Zhang Q; Walker C
    Am J Ther; 2006; 13(6):466-72. PubMed ID: 17122525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study.
    Elliott T; Beca S; Beharry R; Tsoukas MA; Zarruk A; Abitbol A
    Diab Vasc Dis Res; 2021; 18(4):14791641211021374. PubMed ID: 34275385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Structured self-monitoring of blood glucose regimens improve glycemic control in poorly controlled Chinese patients on insulin therapy: Results from COMPASS.
    Ji L; Su Q; Feng B; Shan Z; Hu R; Xing X; Xue Y; Yang T; Hua Y
    J Diabetes; 2017 May; 9(5):495-501. PubMed ID: 27249791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Liraglutide hospital discharge trial: A randomized controlled trial comparing the safety and efficacy of liraglutide versus insulin glargine for the management of patients with type 2 diabetes after hospital discharge.
    Pasquel FJ; Urrutia MA; Cardona S; Coronado KWZ; Albury B; Perez-Guzman MC; Galindo RJ; Chaudhuri A; Iacobellis G; Palacios J; Farias JM; Gomez P; Anzola I; Vellanki P; Fayfman M; Davis GM; Migdal AL; Peng L; Umpierrez GE
    Diabetes Obes Metab; 2021 Jun; 23(6):1351-1360. PubMed ID: 33591621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE; Bhosekar V; Kawamori R
    Vasc Health Risk Manag; 2016; 12():9-12. PubMed ID: 26855580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Longitudinal changes in glycated haemoglobin following treatment intensification after inadequate response to two oral antidiabetic agents in patients with type 2 diabetes.
    Kim K; Unni S; Brixner DI; Thomas SM; Olsen CJ; Sterling KL; Mitchell M; McAdam-Marx C
    Diabetes Obes Metab; 2019 Jul; 21(7):1725-1733. PubMed ID: 30848039
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of 1:1 Fixed-Ratio Combination of Insulin Glargine and Lixisenatide Versus Lixisenatide in Japanese Patients With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs: The LixiLan JP-O1 Randomized Clinical Trial.
    Watada H; Takami A; Spranger R; Amano A; Hashimoto Y; Niemoeller E
    Diabetes Care; 2020 Jun; 43(6):1249-1257. PubMed ID: 32295808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.